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ORIGINAL ARTICLE / ÖZGÜN ARAŞTIRMA 
Osteogenic potency of human bone marrow mesenchymal stem cells from femoral 
atrophic non-union fracture site
Femoral atrofik birleşmemiş kırık yerinden alınan insan kemik iliği mezenkimal kök hücresinin 
osteogenic potansiyeli
Ismail Hadisoebroto Dilogo1, Erica Kholinne1, Phedy Phedy1, Yoshi Pratama Djaja1, Yuyus Kusnadi2, Lakshmi Sandhow2
ÖZET
Amaç: Bu çalışmanın amacı atrofik birleşmemiş kırık pa-
tofizyolojisini daha iyi anlamak için bu bölgelerdeki me-
zenkimal kök hücrelerinin (MKH) osteojenik potansiyelini 
araştırmaktır.
Yöntemler: Çalışmamız in vitro deneysel bir çalışmadır. 
Altı yıllık sağ femurda atrofik birleşmemiş kıık öyküsü bu-
lunan bir hastanın kırık yerinden örnek alındı. Mezenkimal 
kök hücreler kırık bölgesinden izole edildi ve besiyerine 
kültüre ekildi. Mezenkimal kök hücrelerinin doğrulanma 
ve daha sonra osteojenik farklılaşması, tek tabakalı MKH 
ve ticari osteojeik ortamda yapıldı. Osteojenik farklılaş-
mayı değerlendirmek için Alizarin kırmızı boya ve alkalen 
fosfataz için kolorimetrik test yapıldı.
Bulgular: Alizarin boyası ile osteoblastik ortamdaki hüc-
relerin çoğu kırmızıya boyandı. Alkalen fosfatazın kolori-
metrtik değerlendirilmesi osteojenik ve kontrol grubunda 
dört dakika sonra pik konsantrasyona ulaştı.
Sonuçlar: Çalışmamızda alkalen fosfataz aktivitesi var-
lığı ve pozitif Alizarin kırmızı boyanması atrofik birleşme-
miş bölgeden alınan MKH’ların osteojenik hücrelere fark-
lılaşma potansiyeli olduğunu gösterdi.
Anahtar kelimeler: Osteojenik potansiyel, mezenkimal 
kök hücre, birleşmemiş kırık
ABSTRACT
Objective: Mesenchymal stem cells (MSCs) exist in the 
site of atrophic non-union fracture. The aim of this study 
was to evaluate the osteogenic potency of MSCs in order 
to have a better understanding of the unclear pathophysi-
ology of atrophic non-union fracture
Methods: This is an in vitro experimental study. Sample 
was obtained from the non-union site of a patient with a 
6-years-history of atrophic non-union fracture of right fe-
mur. The MSCs was isolated from the fracture site and 
was cultured in the growth medium. Confirmation of the 
MSCs  was  performed  and  then  osteogenic  differentia-
tion was performed in mono-layered MSC grown in both 
home-made and commercial osteogenic media. To evalu-
ate the osteogenic differentiation, we performed Alizarin 
red staining and colorimetric assay for alkaline phospha-
tase (ALP).
Results: From Alizarin red staining, most cells in the os-
teoblast medium were stained red by the staining. The 
result of colorimetric assessment of ALP shows that peak 
concentration was reached after 4 minutes in osteogenic 
group and control group.
Conclusion: The presence of ALP activity and positive 
Alizarin red staining in our study showed that MSCs stem 
cells obtained from site of atrophic non-union is capable 
to be differentiated into osteogenic cells. J Clin Exp Invest 
2014; 5 (2): 159-163
Key words:  Osteogenic  potency,  Mesenchymal  stem 
cell, non-union fracture
INTRODUCTION
Non-union fracture is one of the most difficult com-
plications in orthopaedic. These cases often require 
readmission and surgery, which exaggerate the cost 
greatly, with an estimate of £13 844.68 for a single 
case of non-union [1,2]. Besides the direct cost, the 
burden from the decreased productivity and quality 
of life also occurs, of which it costs $18 712 USD for 
one case [3].
Effective  treatment  can  only  be  done  if  sur-
geon understands the underlying pathophysiology I. H. Dilogo et al. Osteogenic potency of human bone marrow mesenchymal stem cells 160
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of non-union [4]. Abundant callus can be found in 
hypertrophic non-union, indicating ubiquitous blood, 
oxygen, and nutrient supply. It is considered to be a 
result of insufficient stability and treatment is direct-
ed toward stabilization of the fracture. In atrophic 
non-union, however, the pathophysiology remains 
unclear.
Dickson et al suggested poor vascularization 
as a cause of atrophic non-union [5]. Arterial occlu-
sion in the ipsilateral extremity was associated with 
a higher rate of delayed union or non-union in open 
fractures of the tibia. However, Brownlow, Reed and 
Simpson found that in the animal model, the atro-
phic non-unions were well vascularized [6].
Centeno et al have reported success in treat-
ment  of  non-union  fractures  by  percutaneous  in-
jection  of  autologous,  culture-expanded,  bone 
marrow-derived mesenchymal stem cells (MSCs). 
It seemed that lack of MSCs was the cause of the 
atrophic non-union fracture [7].
In our previous study, we found that MSCs exist 
in the site of atrophic non-union fracture [8]. How-
ever, whether they are capable to differentiate into 
osteoblast was not evaluated. In the present study, 
we evaluate the osteogenic potency of MSCs from 
site of atrophic non-union fracture. Understanding 
the osteogenic potency of MSCs from site of atro-
phic non-union will help in better understanding of 
the unclear pathophysiology of atrophic non-union 
fracture.
METHODS
This was an in vitro experimental study. The study 
was  conducted  in  Cipto  Mangunkusumo  Hospital 
and Regenerative and Cellular Therapy (ReGeniC) 
laboratory in Jakarta, Indonesia during the periods 
of July-December 2012. Sample was obtained from 
the non-union site of a 23-year-old patient with a 
6-years-history  of  atrophic  non-union  fracture  of 
right femur. During open reduction and internal fixa-
tion for atrophic non-union fracture, and before re-
canalization of the fracture, a 10 ml syringe prefilled 
with 2 ml heparin 1000 IU/ml was introduced until it 
reached the medullary canal. The plunger was then 
pulled to aspirate the marrow. The procedure was 
repeated until 10 ml of marrow was obtained. The 
surgery  was  then  continued  following  the  routine 
procedure.
Equivalent amount of phosphate buffer saline 
(PBS) was added to marrow aspirate. The solution 
was centrifuged at 3000 rpm, 20°C for 30 minutes. 
Pellet was re-suspended into a 75 cm2 TC flasks 
with  growth  medium  that  contained  low  glucose 
Dulbecco’s modified eagles medium (Gibco, Grand 
Island, New York) containing 1000 mg/L D-glucose, 
L-glutamine, 100 mg/L sodium pyruvate, and 10% 
fetal bovine serum. The suspension was incubated 
at 37°C, 20% oxygen and 5% CO2 flow. After 7 days, 
the culture was washed several times with PBS and 
the medium was replaced with fresh medium every 
3 day until confluence.
Confirmation of mesenchymal stem cells was 
performed  by  flowcytometry.  MSCs  were  washed 
with  PBS/2%  FBS  and  incubated  for  30  minutes 
in  PE-conjugated  mouse  monoclonal  anti-human 
CD73  (BD  Biosciences,  San  Jose,  CA),  PE-con-
jugated  mouse  monoclonal  anti-CD105  (Abcam, 
Cambridge,  UK),  FITC-conjugated  mouse  mono-
clonal anti-CD45 (BD Biosciences, San Jose, CA), 
FITC-conjugated  mouse  monoclonal  anti-human 
CD34 (BD Biosciences, San Jose, CA), PE-conju-
gated mouse monoclonal anti-CD19 (Abcam, Cam-
bridge, UK), or PE-conjugated mouse monoclonal 
anti-HLA-DR+DP+DQ  (Abcam,  Cambridge,  UK), 
or FITC-conjugated mouse monoclonal anti-CD14 
(Abcam, Cambridge, UK) antibody. The expression 
of corresponding markers were detected with flow 
cytometry (FACSCalibur, Franklin Lakes, NJ) and 
analyzed with CellQuestPro Software.
Once the MSCs culture reach confluence, os-
teogenic  differentiation  was  performed  in  mono-
layered MSC grown in both home-made and com-
mercially available osteogenic media (MesenCult®) 
and incubated 37°C, 20% oxygen and 5% CO2 flow. 
Home-made medium contained DMEM, 10% FBS, 
1% antibiotics, 0.1μM dexamethasone, 50μM ascor-
bate-2-phosphate, 10mM β-glycerophosphate.
After 7 day, cells culture was washed several 
times with PBS and the medium was replaced with 
fresh medium every 3 day until confluence. Con-
fluence  in  commercially  available  medium  was 
reached in 5 weeks while all cells in the home-made 
medium failed to survive. 
To evaluate osteogenic differentiation, we per-
formed Alizarin red staining and colorimetric assay 
for  alkaline  phosphatase  (ALP).  Undifferentiated 
mesenchymal  stem  cells  were  used  as  negative 
control. Colorimetric assay was performed using Al-
kaline Phosphatase Colorimetric Assay Kit (Abcam, 
Cambridge,  UK)  containing  p-nitrophenyl  phos-
phate (pNPP) as a phosphatase substrate. Amount 
of 25 micro liter of cell lysate was prepared using 
three cycles of freeze-thaw in de-ionized distilled 
water. The cells lysate was added to a well plate I. H. Dilogo et al. Osteogenic potency of human bone marrow mesenchymal stem cells 161
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with  assay  buffer  and  pNPP.  The  samples  were 
shielded from direct light at room temperature for 1 
h. Afterward, L Stop Solution (3N NaOH) was added 
to the wells and the plate was read at 405 nm in a 
micro-plate reader. 
RESULTS
After 3 weeks, the MSCs were successfully isolated 
and expanded as observed by BMSCs attachment 
with fibroblast-like morphology appearance in a light 
microscope with 100x magnification. They were ad-
herent to the TC flask and was not washed in the 
medium replacement. The confluence of cells was 
80%-90% with total number of the cells 3.6 x106 
and 2.2x106. (Figure 1) The MSCs characteristic 
was confirmed with ≥95% expression of CD105 and 
CD73 as well as its low expression (≤2%) of CD14, 
CD34, CD45, CD19, and HLA-DR.
Figure 1. Microscopic evaluation of mesenchymal stem cells (x100).
(a) The first week isolation of BMSCs , the mononuclear cells is adhered to the Tissue Culture Flask undergo periodic 
medium replacement
(b) On day 5, MSCs were detected with fibroblast-like cells morphology
(c) The end of second week, most of the them are fibroblast like cells adhered to Tissue Culture Flask, minimal mono-
nuclear cells were observed
(d) The end of third week, 90% of cell confluence, indicating the differentiation process to proceed
Figure 2. Shows the result of Alizarin red staining of cells in osteogenic medium in comparison to control after 5 weeks 
of cells culture. Most cells in the osteoblast medium were stained red by the staining
Microscopic evaluation of osteogenic differentiation (alizarin red staining, x100)
(a) control MSCs in growth medium; (b) MSCs in osteogenic medium stained with Alizarin RedI. H. Dilogo et al. Osteogenic potency of human bone marrow mesenchymal stem cells 162
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lagen I, TGF-B and fibronectin. Matrix maturation 
phase is characterized by maximal expression of 
alkaline phosphatase. During matrix mineralization, 
proteins  such  as  osteocalsin,  bone  sialoprotein, 
and osteopontin are expressed, Calcium deposition 
during this phase can also be evaluated using ad-
equate staining methods such as Alizarin red.
Marom et al reported ALP was expressed dur-
ing early stage of differentiation and was involved 
with matrix mineralization.[16] Alizarin red is a stain-
ing  method  to  determine  the  presence  of  calcific 
deposition by cells of an osteogenic lineage during 
mineralization phase. It is an early stage marker of 
matrix mineralization [17-18]. The presence of ALP 
activity and positive Alizarin red staining in our study 
showed that MSCs stem cells obtained from site of 
atrophic non-union is capable to be differentiated 
into osteogenic cells.
Although our study is limited only to one sam-
ple, it is a preliminary result for further evaluation 
of osteogenic potency of mesenchymal stem cells 
obtained from site of atrophic non-union. Confirma-
tion of this finding will lead to better understanding 
of pathophysiology of atrophic non-union and im-
provement in management strategy.
In conclusion, our preliminary study found the 
possible osteogenic potency of mesenchymal stem 
cells obtained from non-union site.
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